ArticleFrontiers in oncology2021
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 40 citations in OpenAlex.
- Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing.Molecular cancer · 2026Trial
- Simultaneous immune checkpoint blockade-associated diabetes mellitus and thyrotoxicosis.JCEM case reports · 2026Article
- Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort study.Journal for immunotherapy of cancer · 2026Article
- Immune-Related Adverse Events and Therapeutic Outcomes After Stopping Immune Checkpoint Inhibitors due to Toxicity Among Patients With Metastatic Melanoma (University Hospitals Sussex).Cancer medicine · 2026Article
- Universal diseased-site targeting via glycolysis-driven lactic acid gradient.Science advances · 2026Article
- Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis.Immuno-oncology technology · 2026Review
- Interferon-primed immune landscapes predict immune-related adverse events during immune checkpoint inhibitor therapy.Frontiers in cell and developmental biology · 2026Article
- Risk factors for cutaneous immune-related adverse events: a systematic scoping review.Frontiers in immunology · 2026Article
- Unexpectedly High Incidence of Immune-Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab-Including Chemotherapy.Annals of gastroenterological surgery · 2026Article
- Advanced Cutaneous Squamous Cell Carcinoma: Biology, Immunotherapy, and Evolving Prognostic Factors.Biomedicines · 2025Review
- Sinonasal mucosal melanoma in an elderly patient: a case report.Journal of medical case reports · 2025Article
- Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.Breast (Edinburgh, Scotland) · 2025Article
- The role of tumor types in immune-related adverse events.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Immune checkpoint inhibitors: From friend to foe.Toxicology reports · 2025Article
- Editorial for "Latest Advances in Diagnosis and Management of Skin Cancer".Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapy.Frontiers in immunology · 2025Article
- Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving Immunotherapies.Clinical lung cancer · 2024Article
- Immune-related [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- The Effect of Body Mass Index on Melanoma Biology, Immunotherapy Efficacy, and Clinical Outcomes: A Narrative Review.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) - that arise from unrestrained immune activation. The link between irAE development and clinical outcome in melanoma and other cancers is inconsistent; and little data exists on the occurrence of multiple irAEs. We sought to characterize development of single and multiple irAEs, and association of irAE(s) development with clinical variables and impact upon outcomes in advanced melanoma patients treated with anti-PD-1 ICIs.
methodsWe conducted a retrospective study of 190 patients with metastatic melanoma treated with single-agent anti-PD-1 ICI therapy between June 2014 and August 2020 at a large integrated network cancer center identified through retrospective review of pharmacy records. irAEs were graded based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
results190 patients were evaluated of whom 114 patients (60.0%) experienced ≥1 irAE, including 30 (15.8%) with grade 3/4 irAEs. The occurrence of any irAE was strongly associated with the development of investigator-assessed response to anti-PD-1 therapy (p < 0.0001); whether evaluated by current (p=0.0082) or best (p=0.0001) response. In patients with ≥2 irAEs, distinct patterns were observed. Median progression-free survival (PFS) and overall survival (OS) were greater in those with any irAE compared to those without (PFS, 28 months
conclusionsIn this study, we demonstrated that irAE occurrence was significantly associated with response to anti-PD-1 therapy and improved PFS/OS. Those who developed multiple irAEs had a trend towards improved PFS and OS compared to those who developed only a single irAE. Increased BMI but neither age nor gender were associated with irAE development. Distinct patterns of irAEs observed suggest shared etiopathogenetic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.